Adaptive Biotechnologies (ADPT)

• Market cap: $2.51B
• 1 day: -1.38%
• 5 days: -4.59%
• 1 month: -12.85%
• 3 months: 9.76%
• 6 months: 40.94%
• Year to date: 165.27%
• 1 year: 168.74%
• 5 years: -72.36%
• 10 years: -59.26%
• Sector: Healthcare
• Industry: Biotechnology

About: Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Employees: 619